Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of VMT01, a targeted alpha-particle therapy, TAT, in patients with histologically confirmed melanoma and positive melanocortin 1 receptor, MC1R, imaging scans. Patients in this cohort are receiving VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb (BMY) as Opdivo. Patients in earlier cohorts received VMT01 as monotherapy. Initial results from the earlier cohorts were previously presented at the 21st International Congress of the Society for Melanoma Research, SMR, in October 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics initiated with a Buy at H.C. Wainwright
- Perspective Therapeutics initiated with a Buy at Brookline
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Perspective Therapeutics initiated with an Outperform at Scotiabank
- Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning
Questions or Comments about the article? Write to editor@tipranks.com